Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Citations to this article

Induction of myelodysplasia by myeloid-derived suppressor cells
Xianghong Chen, … , Alan List, Sheng Wei
Xianghong Chen, … , Alan List, Sheng Wei
Published October 15, 2013
Citation Information: J Clin Invest. 2013;123(11):4595-4611. https://doi.org/10.1172/JCI67580.
View: Text | PDF
Research Article Hematology Article has an altmetric score of 28

Induction of myelodysplasia by myeloid-derived suppressor cells

  • Text
  • PDF
Abstract

Myelodysplastic syndromes (MDS) are age-dependent stem cell malignancies that share biological features of activated adaptive immune response and ineffective hematopoiesis. Here we report that myeloid-derived suppressor cells (MDSC), which are classically linked to immunosuppression, inflammation, and cancer, were markedly expanded in the bone marrow of MDS patients and played a pathogenetic role in the development of ineffective hematopoiesis. These clonally distinct MDSC overproduce hematopoietic suppressive cytokines and function as potent apoptotic effectors targeting autologous hematopoietic progenitors. Using multiple transfected cell models, we found that MDSC expansion is driven by the interaction of the proinflammatory molecule S100A9 with CD33. These 2 proteins formed a functional ligand/receptor pair that recruited components to CD33’s immunoreceptor tyrosine-based inhibition motif (ITIM), inducing secretion of the suppressive cytokines IL-10 and TGF-β by immature myeloid cells. S100A9 transgenic mice displayed bone marrow accumulation of MDSC accompanied by development of progressive multilineage cytopenias and cytological dysplasia. Importantly, early forced maturation of MDSC by either all-trans-retinoic acid treatment or active immunoreceptor tyrosine-based activation motif–bearing (ITAM-bearing) adapter protein (DAP12) interruption of CD33 signaling rescued the hematologic phenotype. These findings indicate that primary bone marrow expansion of MDSC driven by the S100A9/CD33 pathway perturbs hematopoiesis and contributes to the development of MDS.

Authors

Xianghong Chen, Erika A. Eksioglu, Junmin Zhou, Ling Zhang, Julie Djeu, Nicole Fortenbery, Pearlie Epling-Burnette, Sandra Van Bijnen, Harry Dolstra, John Cannon, Je-in Youn, Sarah S. Donatelli, Dahui Qin, Theo De Witte, Jianguo Tao, Huaquan Wang, Pingyan Cheng, Dmitry I. Gabrilovich, Alan List, Sheng Wei

×

Total citations by year

Year: 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2009 Total
Citations: 7 12 15 26 28 22 15 17 13 18 14 3 1 191
Citation information
This citation data is accumulated from CrossRef, which receives citation information from participating publishers, including this journal. Not all publishers participate in CrossRef, so this information is not comprehensive. Additionally, data may not reflect the most current citations to this article, and the data may differ from citation information available from other sources (for example, Google Scholar, Web of Science, and Scopus).

Citations to this article in year 2017 (13)

Title and authors Publication Year
Targeting innate immunity to downmodulate adaptive immunity and reverse type 1 diabetes
A Itoh, WM Ridgway
ImmunoTargets and Therapy 2017
MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia
AR Pyzer, D Stroopinsky, H Rajabi, A Washington, A Tagde, M Coll, J Fung, MP Bryant, L Cole, K Palmer, P Somaiya, RK Leaf, M Nahas, A Apel, S Jain, M McMasters, L Mendez, J Levine, R Joyce, J Arnason, PP Pandolfi, D Kufe, J Rosenblatt, D Avigan
Blood 2017
Stem and progenitor cell alterations in myelodysplastic syndromes
A Shastri, B Will, U Steidl, A Verma
Blood 2017
Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858
EA Eksioglu, X Chen, KH Heider, B Rueter, KL McGraw, AA Basiorka, M Wei, A Burnette, P Cheng, J Lancet, R Komrokji, J Djeu, A List, S Wei
Leukemia 2017
The microenvironment in myelodysplastic syndromes: niche-mediated disease initiation and progression
AJ Li, LM Calvi
Experimental Hematology 2017
S100A8/A9 increases the mobilization of pro-inflammatory Ly6Chigh monocytes to the synovium during experimental osteoarthritis
NA Cremers, MH van Bosch, S Dalen, ID Ceglie, G Ascone, F de Loo, M Koenders, P der Kraan, A Sloetjes, T Vogl, J Roth, EJ Geven, AB Blom, PL van Lent
Arthritis Research & Therapy 2017
Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment
O Gbolahan, A Zeidan, M Stahl, MA Zaid, S Farag, S Paczesny, H Konig
International journal of molecular sciences 2017
Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes
T Cluzeau, KL McGraw, B Irvine, E Masala, L Ades, AA Basiorka, J Maciejewski, P Auberger, S Wei, P Fenaux, V Santini, A List
Haematologica 2017
NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome
EA Griffiths, P Srivastava, J Matsuzaki, Z Brumberger, ES Wang, J Kocent, A Miller, GW Roloff, HY Wong, BE Paluch, LG Lutgen-Dunckley, BL Martens, K Odunsi, AR Karpf, CS Hourigan, MJ Nemeth
Clinical cancer research 2017
Mass cytometry deep phenotyping of human mononuclear phagocytes and myeloid-derived suppressor cells from human blood and bone marrow.
Roussel M, Ferrell PB Jr, Greenplate AR, Lhomme F, Le Gallou S, Diggins KE, Johnson DB, Irish JM
Journal of leukocyte biology 2017
骨髓增生异常综合征骨髓微环境异常的研究进展
2017
[Research progress of bone marrow microenvironment abnormalities in myelodysplastic syndrome].
Dong PY, Huang LF, Sun HY
Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2017
Is Disease-Specific Immunotherapy a Potential Reality for MDS?
Sallman DA, Davila ML
Clinical Lymphoma, Myeloma & Leukemia 2017

Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Picked up by 2 news outlets
Blogged by 1
Posted by 1 X users
Referenced in 69 patents
223 readers on Mendeley
See more details